SEC Tracker
Get the app

Metagenomi Therapeutics MGX

Metagenomi Therapeutics announces FDA clearance for MGX-001

Metagenomi Therapeutics (MGX) filed an 8-K with the SEC on Nov 10, 2026, 4:08 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. MGX-001 received FDA clearance for Phase 1/2 trial in hemophilia A
  2. Cash position of $101.7 million as of September 30, 2026
  3. R&D expenses decreased to $17.5 million in Q3 2026
  4. INTEGR8 trial planned for first half of 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Metagenomi Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.